全文获取类型
收费全文 | 1714篇 |
免费 | 135篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 39篇 |
妇产科学 | 2篇 |
基础医学 | 138篇 |
临床医学 | 143篇 |
内科学 | 1004篇 |
皮肤病学 | 7篇 |
神经病学 | 4篇 |
特种医学 | 43篇 |
外科学 | 246篇 |
综合类 | 198篇 |
现状与发展 | 1篇 |
预防医学 | 24篇 |
药学 | 69篇 |
中国医学 | 18篇 |
肿瘤学 | 24篇 |
出版年
2024年 | 1篇 |
2023年 | 58篇 |
2022年 | 86篇 |
2021年 | 97篇 |
2020年 | 105篇 |
2019年 | 95篇 |
2018年 | 80篇 |
2017年 | 63篇 |
2016年 | 76篇 |
2015年 | 58篇 |
2014年 | 86篇 |
2013年 | 115篇 |
2012年 | 77篇 |
2011年 | 93篇 |
2010年 | 61篇 |
2009年 | 60篇 |
2008年 | 79篇 |
2007年 | 73篇 |
2006年 | 63篇 |
2005年 | 72篇 |
2004年 | 53篇 |
2003年 | 50篇 |
2002年 | 37篇 |
2001年 | 34篇 |
2000年 | 33篇 |
1999年 | 31篇 |
1998年 | 26篇 |
1997年 | 21篇 |
1996年 | 34篇 |
1995年 | 17篇 |
1994年 | 27篇 |
1993年 | 17篇 |
1992年 | 14篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 15篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1979年 | 2篇 |
排序方式: 共有1962条查询结果,搜索用时 406 毫秒
41.
42.
Overlap syndromes among autoimmune liver diseases 总被引:4,自引:0,他引:4
The three major immune disorders of the liver are autoimmune hepatitis(AIH),primary biliary cirrhosis(PBC) and primary sclerosing cholangitis(PSC).Variant forms of these diseases are generally called overlap syndromes,although there has been no standardised definition.Patients with overlap syndromes present with both hepatitic and cholestatic serum liver tests and have histological features of AIH and PBC or PSC.The AIH-PBC overlap syndrome is the most common form,affecting almost 10% of adults with AIH or PBC.Single cases of AIH and autoimmune cholangitis(AMA-negative PBC) overlap syndrome have also been reported.The AIH-PSC overlap syndrome is predominantly found in children,adolescents and young adults with AIH or PSC.Interestingly,transitions from one autoimmune to another have also been reported in a minority of patients,especially transitions from PBC to AIH-PBC overlap syndrome.Overlap syndromes show a progressive course towards liver cirrhosis and liver failure without treatment.Therapy for overlap syndromes is empiric,since controlled trials are not available in these rare disorders.Anticholestatic therapy with ursodeoxycholic acid is usually combined with immunosuppressive therapy with corticosteroids and/or azathioprine in both AIH-PBC and AIH-PSC overlap syndromes.In end-stage disease,liver transplantation is the treatment of choice. 相似文献
43.
Kim JH Kim BH Kim YW Park JC Jung YH Lee BO Han YS Dong SH Kim HJ Chang YW Lee JI Chang R 《Journal of gastroenterology and hepatology》2004,19(11):1324-1327
Autoimmune cholangitis is characterized biochemically by chronic cholestasis and histopathologically by chronic non-suppurative destructive cholangitis. It is associated with positive antinuclear antibody test and negative antimitochondrial antibody test results. Recently, we experienced a case of a 35-year-old woman with autoimmune cholangitis associated with thymoma who presented with pruritis, jaundice, chronic fatigue and anterior chest discomfort. Her laboratory examinations revealed marked increases in levels of serum alkaline phosphatase and gamma-glutamyl transpeptidase. In serological tests, antinuclear antibody was found, but antimitochondrial antibody was not. Liver biopsy findings were compatible with chronic non-suppurative destructive cholangitis. On computed tomography (CT) of the chest, a large anterior mediastinal mass was found. The mass was totally resected and the patient was treated with ursodeoxy cholic acid. Thereafter, her clinical symptoms improved and liver functions completely returned to the normal range. We describe here an uncommon association of autoimmune cholangitis with thymoma, which has not been reported previously in the English-written literature. 相似文献
44.
45.
Paul C. van de Meeberg Frank H. J. Wolfhagen Gerard P. Van Berge-Henegouwen Jan M. J. I. Salemans Albert Tangerman Henk R. van Buuren Jan van Hattum Karel J. van Erpecum 《Journal of hepatology》1996,25(6):887-894
Background: Ursodeoxycholic acid (UDCA) improves liver biochemistry in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Since UDCA acts partly by reducing the intestinal absorption of hydrophobic endogenous bile salts and is poorly absorbed from the intestine, a multiple dose regimen has been advocated. Single dose treatment, on the other hand, may improve compliance.Aim: The effects of a single or multiple dose regimen on liver enzymes and serum and biliary bile salts composition were evaluated.Methods: Twenty-seven patients (19 PSC, 8 PBC), most with early stage disease, received UDCA (10 mg kg−1 day−1) in a single dose at bed time (n=13) or in three divided gifts with meals (n=14) over 3 months. Five patients had both treatment regimens in random order with a 1-month wash-out period in between.Results: Liver biochemistry equally improved in both groups. Biliary enrichment (% UDCA of total bile salts, mean±SEM) was 40.1±2.4 in the single dose group vs 40.8±2.8 in the multiple dose group (p=NS) and was positively correlated with biochemical improvement (AP: r=0.47, p=0.02; GGT: r=0.58, p=0.002; ASAT: r=0.67, p=0.002; ALAT: r=0.52, p=0.01). Biochemical improvement was not correlated with the concentration or %UDCA in serum. Patients participating in the cross-over design had comparable biochemical response and biliary %UDCA during both regimens.Conclusion: Single and multiple dose UDCA have similar effects on liver biochemistry and biliary enrichment in cholestatic liver disease. Biochemical improvement appears to be related to biliary (but not serum) enrichment with UDCA. 相似文献
46.
Domajnko B Ahrendt SA 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2005,7(4):292-297
Primary sclerosing cholangitis (PCS) is a progressive disease leading to secondary biliary cirrhosis. Patients are at increased risk of developing cholangiocarcinoma, which is usually diagnosed at an advanced stage. Treatment of PCS includes medical therapy, endoscopic biliary dilation, percutaneous transhepatic stenting, extrahepatic biliary resection and liver transplantation. The most effective management of primary sclerosing cholangitis before the onset of cirrhosis remains unclear. Non-transplant surgical procedures have a limited but defined role in patients with PCS. Resection of the extrahepatic biliary tree in symptomatic non-cirrhotic patients improves hyperbilirubinaemia and prolongs both transplant-free and overall survival when compared with non-operative dilation and/or stenting. Surgical resection may also definitively establish or exclude a diagnosis of cholangiocarcinoma in patients with dominant extrahepatic or perihilar strictures. Extrahepatic bile duct resection may also reduce the risk of cholangiocarcinoma. Extrahepatic biliary resection should be considered in selected non-cirrhotic patients with symptomatic biliary obstruction and dominant extrahepatic and/or perihilar strictures. Those patients in whom cholangiocarcinoma is suspected should also undergo resection. 相似文献
47.
Michael B. Albert MD William M. Steinberg MD James P. Henry BS 《Digestive diseases and sciences》1988,33(10):1223-1225
The purpose of the present study was to examine the relationship between the tumor marker, CA19-9, and benign biliary tract disease. We measured serum and bile CA19-9 in 40 patients with (1) symptomatic cholelithiasis (N=14), (2) common bile duct obstruction without cholangitis (N=8), (3) acute cholangitis secondary to gallstone disease (N=7), and (4) acute cholecystitis (N=11). All seven patients with acute cholangitis had marked elevations of serum CA19-9 (range 190-32,000 units/ml; 75 units/ml cutoff), whereas none of the patients in the other groups had elevated levels despite similar degrees of cholestasis and similarly high levels of CA19-9 in gallbladder and common duct bile (range 7.3×104–2.3×109 units/ml). Of the three patients with cholangitis in whom CA19-9 levels were followed serially, all had rapid return of levels to normal after successful treatment. We conclude that the tumor marker CA19-9 is markedly elevated in the serum of patients with acute cholangitis but not in patients with other forms of benign biliary tract disease. 相似文献
48.
Aristeidis Grigoriadis Fabian Morsbach Nikolaos Voulgarakis Karouk Said Annika Bergquist Nikolaos Kartalis 《Scandinavian journal of gastroenterology》2020,55(2):228-235
AbstractObjectives: Interpretation of MRI/MRCP in primary sclerosing cholangitis (PSC) at a single time point has low inter-reader agreement. Agreement of interpretation of the dynamic course of duct changes in follow-up MRI/MRCP is of clinical importance but remains unknown. Our aims are therefore to assess the inter-reader agreement of interpretation of the course of duct changes in PSC and investigate if elimination of 3?D MRCP affects inter-reader agreement.Materials and Methods: We studied 40 consecutive PSC-patients who underwent two liver MRI/MRCPs at two time points. Two readers independently evaluated the course of duct changes between the two time points in two imaging sets, one with and one without 3?D MRCP. The intraclass correlation coefficient (ICC) was calculated for evaluation of inter-reader and intra-reader agreement between the two time points and two imaging sets accordingly.Results: Inter-reader agreement of the interpretation of the course of duct changes between the two time points was poor (ICC up to 0.224). Elimination of 3?D MRCP neither improved inter-reader agreement which was again poor (ICC up to 0.26) nor did it change considerably the way readers interpret the course of ducts changes (ICC for intra-reader agreement between 0.809 and 0.978).Conclusions: Inter-reader agreement of the interpretation of radiological course of duct changes is poor in serial follow-up MRI/MRCP of PSC-patients. Elimination of 3?D MRCP does not increase inter-reader agreement but maintains an excellent intra-reader agreement for the interpretation of the dynamic course of bile duct changes.
- Key points
Inter-reader agreement of interpretation of radiological course of bile duct changes between serial follow-up MRI/MRCP examinations of patients with PSC is poor.
Absence of 3D MRCP does not affect considerably the way readers interpret the radiological course of bile ducts changes.
When MRCP is absent or of low quality, utilization of other sequences seems to be helpful as an alternative for bile duct evaluation.
49.
Cheng-Peng Zhong Zhi-Feng Xi Qiang Xia 《Hepatobiliary & pancreatic diseases international : HBPD INT》2018,17(1):27-31
Background: Autoimmune liver diseases(ALDs) consist of autoimmune hepatitis(AIH), primary biliary cirrhosis(PBC), primary sclerosing cholangitis(PSC), Ig G4-associated cholangitis and overlap syndromes.Patients with these diseases may gradually progress to end-stage liver diseases and need liver transplantation. The present study aimed to explore the prognosis of patients with ALDs after liver transplantation.Methods: The clinical data of 80 patients with ALD(24 cases of AIH, 35 of PBC, 15 of PSC and 6 of AIHPBC overlap syndromes) who underwent liver transplantation in Renji Hospital, Shanghai Jiao Tong University School of Medicine from June 2004 to September 2016 were collected retrospectively. The causes of death were analyzed and the postoperative cumulative survival rate was estimated by the Kaplan–Meier method. Recurrence and other complications were also analyzed.Results: Of the 80 patients, 18 were males and 62 were females. The average age was 50.5 years and the average Model for End-stage Liver Disease(MELD) score was 14.1. After a median follow-up of 19.8 months, 8 patients died. The 1-, 3-and 5-year cumulative survival rates were all 89.0%. Three cases of recurrent ALDs were diagnosed(3.8%) but they were not totally consistent with primary diseases. Biliary tract complication occurred in 10 patients(12.5%). The new onset of tumor was observed in 1 patient(1.3%). De novo HBV/CMV/EBV infection was found in 3, 8 and 3 patients, respectively.Conclusion: Liver transplantation is an effective and safe treatment for end-stage ALD. 相似文献
50.